Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ticagrelor 90 mg - film-coated tablet - ticagrelor

Saudo Arabija - anglų - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - ticagrelor - film-coated tablet - 90 mg,

Europos Sąjunga - anglų - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antithrombotic agents - kengrexal, co-administered with acetylsalicylic acid (asa), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (pci) who have not received an oral p2y12 inhibitor prior to the pci procedure and in whom oral therapy with p2y12 inhibitors is not feasible or desirable.

Singapūras - anglų - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - 90 mg - ticagrelor 90 mg

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 90mg;  ;  ;   - film coated tablet - 90 mg - active: ticagrelor 90mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide yellow macrogol 400 magnesium stearate mannitol purified talc purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - brilique, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (acs) ora history of myocardial infarction (mi) and a high risk of developing an atherothrombotic eventbrilique, co-administered with acetyl salicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - possia, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-st-elevation myocardial infarction [nstemi] or st-elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 60mg;  ;  ;   - film coated tablet - 60 mg - active: ticagrelor 60mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide black iron oxide red macrogol 400 magnesium stearate mannitol purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Kanada - anglų - Health Canada

chiesi farmaceutici s.p.a. - cangrelor (cangrelor tetrasodium) - powder for solution - 50mg - cangrelor (cangrelor tetrasodium) 50mg

Kanada - anglų - Health Canada

astrazeneca canada inc - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors